Compare PAY & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAY | TARS |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2021 | 2020 |
| Metric | PAY | TARS |
|---|---|---|
| Price | $28.02 | $67.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $36.29 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.4M | 890.8K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.57 | 48.21 |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $1,196,507,000.00 | $451,360,000.00 |
| Revenue This Year | $18.60 | $56.43 |
| Revenue Next Year | $18.89 | $30.19 |
| P/E Ratio | $178.19 | ★ N/A |
| Revenue Growth | 37.25 | ★ 146.71 |
| 52 Week Low | $20.11 | $38.51 |
| 52 Week High | $39.38 | $85.25 |
| Indicator | PAY | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 70.42 | 59.94 |
| Support Level | $26.65 | $65.62 |
| Resistance Level | $29.88 | $77.35 |
| Average True Range (ATR) | 1.16 | 3.79 |
| MACD | 0.89 | 0.70 |
| Stochastic Oscillator | 88.25 | 74.80 |
Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers through a Software-as-a-Service (SaaS), secure, omni-channel technology platform. The platform integrates with a biller's financial and operational systems to provide secure and flexible processing of payments, including credit cards, debit cards, eChecks, and digital wallets, across multiple channels such as online, mobile, IVR, call centers, chatbots, and voice-based assistants. The company generates the majority of its revenue from payment transaction fees processed through its platform. Geographically, it derives the maximum revenue from the United States.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.